List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 12 studies with search of:   "Miglustat"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Terminated Miglustat / OGT 918 in the Treatment of Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Drug: miglustat;   Drug: placebo
2 Active, not recruiting Miglustat in Niemann-Pick Type C Disease
Condition: Niemann-Pick Type C Disease
Intervention: Drug: miglustat
3 Active, not recruiting Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease
Condition: Type 1 Gaucher Disease
Intervention: Drug: miglustat
4 Completed Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses
Conditions: GM2 Gangliosidoses;   Tay-Sachs;   Sandhoff Disease
Intervention: Drug: Zavesca (Miglustat)
5 Active, not recruiting Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis
Condition: Gangliosidoses GM2
Intervention: Drug: miglustat
6 Recruiting Miglustat in Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Drug: miglustat;   Drug: placebo
7 Completed Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)
Condition: Contraception
Intervention: Drug: Miglustat (Zavesca)
8 Completed OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: OGT 918
9 Completed Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease
Condition: Niemann Pick Diseases
Intervention: Drug: OGT918
10 Completed Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex
Condition: HIV Infections
Intervention: Drug: Butyldeoxynojirimycin
11 Completed Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3
Condition: HIV Infections
Interventions: Drug: Butyldeoxynojirimycin;   Drug: Zidovudine
12 Completed Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)
Condition: HIV Infections
Interventions: Drug: Butyldeoxynojirimycin;   Drug: Zidovudine

  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services